SCHEMBL16634428

SCHEMBL16634428

CCCCCC(C(=O)NO)c1c[nH]c2ccccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 3/20 0.55
HDAC1 Q13547 3/20 0.55
HDAC2 Q92769 3/20 0.55
HDAC10 Q969S8 3/20 0.55
HDAC11 Q96DB2 3/20 0.55
HDAC8 Q9BY41 3/20 0.55
HDAC9 Q9UKV0 3/20 0.55
HDAC5 Q9UQL6 3/20 0.55
HDAC4 P56524 2/20 0.55
HDAC7 Q8WUI4 2/20 0.55
HDAC6 Q9UBN7 2/20 0.55
GPR84 Q9NQS5 2/20 0.51
FFAR1 O14842 1/20 0.51
MMP2 P08253 5/20 0.48
MMP9 P14780 5/20 0.48
MMP8 P22894 5/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
MAPT P10636 1/20 0.47
PKM P14618 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28860693 0.85 MEN1 (0.59) HDAC3HDAC1HDAC2HDAC10HDAC11
SCHEMBL28224613 0.84 HDAC3 (0.51) HDAC3HDAC1HDAC2HDAC10HDAC11
SCHEMBL21067833 0.82 MEN1 (0.61) HDAC3HDAC1HDAC2HDAC10HDAC11
SCHEMBL4858383 0.82 MEN1 (0.61) HDAC3HDAC1HDAC2HDAC10HDAC11
SCHEMBL28224620 0.81 GPR84 (0.52) HDAC3HDAC1HDAC2HDAC10HDAC11
SCHEMBL19612657 0.81 GPR84 (0.55) HDAC3HDAC1HDAC2HDAC10HDAC11
SCHEMBL4592076 0.78 ECE1 (0.48) HDAC3HDAC1HDAC2HDAC10HDAC11
SCHEMBL8959988 0.77 GPR84 (0.60) HDAC3HDAC1HDAC2HDAC10HDAC11
SCHEMBL5822295 0.77 GPR84 (0.79) HDAC3HDAC1HDAC2HDAC10HDAC11
SCHEMBL28287011 0.76 GPR84 (0.56) HDAC3HDAC1HDAC2HDAC10HDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206124-B2 Treatment of drug-resistant cancer with 2-aryl-2-(3-indolyl) acetohydroxamates NEW MEXICO TECHNICAL RESEARCH FOUNDATION (US) 2015-12-08 US disclosed
US-9206124-B2 Treatment of drug-resistant cancer with 2-aryl-2-(3-indolyl) acetohydroxamates NEW MEXICO TECHNICAL RESEARCH FOUNDATION (US) 2015-12-08 US disclosed
US-20150105439-A1 TREATMENT OF DRUG-RESISTANT CANCER WITH 2-ARYL-2-(3-INDOLYL) ACETOHYDROXAMATES NEW MEXICO TECH UNIVERSITY RESEARCH PARK CORPORATION 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105439-A1 TREATMENT OF DRUG-RESISTANT CANCER WITH 2-ARYL-2-(3-INDOLYL) ACETOHYDROXAMATES AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ABCC1 HDAC3 4/4885HDAC1 65/4885HDAC2 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.